Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Real-time Quote. Real-time Tradegate - 08/31 06:05:10 pm
73.505 EUR   -0.02%
08/29 DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendmen..
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UCB : Acquisition of own shares in the framework of employees’ long-term incentive plans

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/04/2011 | 08:05pm CEST

BRUSSELS, Belgium, 4 August 2011 – 19:30 (CET) – regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired 7,600 UCB shares on the Brussels stock exchange on the dates and at the prices indicated hereunder:

Date

Price EUR

Amount

03/08/2011

31.6376

600

03/08/2011

31.20

2,000

02/08/2011

31.48

2,500

29/07/2011

32.23

500

29/07/2011

32.49

2,000

These shares were immediately distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company’s share option plans of which the detail is given in UCB annual report.

UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608

For further information antje.witte@ucb.com

Antje Witte, Investor Relations, UCB

T +32.2.559.9414,

Michael.tuck-sherman@ucb.com

Michael Tuck-Sherman, Investor Relations, UCB

T +32.2.559.9712,

About UCB ) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB). www.ucb.com

UCB, Brussels, Belgium (

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
08/29 DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
08/14 UCB : U.S. District Court confirms validity of patent for UCB's Vimpat®
08/05 AMPHASTAR PHARMACEUTICALS : Purchases International Medication Systems (UK) Limi..
07/28 UCB : continues to deliver on its growth strategy
07/25 AMGEN : UCB and Amgen submit biologics license application for Romosozumab to th..
07/05 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
07/04 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VI..
06/10 UCB : bimekizumab demonstrates positive results in early development in patients..
More news
Sector news : Pharmaceuticals - NEC
05:32pDJSHIRE : Files 8K - Other Events
01:45pDJASTRAZENECA : Agrees to Pay $5.5 Million to Settle Alleged Bribery Probe
01:35pDJASTRAZENECA : Agrees to Pay $5.5 Million to Settle Alleged Bribery Probe
02:55aDJWALGREENS BOOTS ALLIANCE : Theranos Walks Away From Zika Test
01:33a ASTRAZENECA : to pay $5.52 million to resolve U.S. SEC foreign bribery case
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/31 UCB S.A. 2016 Q1 - Results - Earnings Call Slides
07/31 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q2 2016 Results - Earnings Call ..
07/22 Amgen submits BLA in U.S. for osteoporosis candidate romosozumab
05/28 LANNETT : Structural Benefits Of The Kremers Acquisition: 100+% Upside
03/21 Amgen's romosozumab successful in late-stage study in men with osteoporosis
Advertisement
Financials (€)
Sales 2016 4 047 M
EBIT 2016 736 M
Net income 2016 463 M
Debt 2016 992 M
Yield 2016 1,72%
P/E ratio 2016 28,24
P/E ratio 2017 23,14
EV / Sales 2016 3,78x
EV / Sales 2017 3,45x
Capitalization 14 300 M
More Financials
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 78,9 €
Spread / Average Target 7,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB-11.95%15 941
JOHNSON & JOHNSON16.31%326 855
ROCHE HOLDING LTD.-12.84%214 220
PFIZER INC.8.05%211 570
NOVARTIS AG-10.83%209 772
ASTRAZENECA PLC7.33%174 031
More Results